Spots Global Cancer Trial Database for ontak
Every month we try and update this database with for ontak cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer | NCT00880360 | Epithelial Ovar... Extraovarian Pe... Fallopian Tube ... | Ontak | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Phase II Trial of Ontak With Metastatic Melanoma | NCT00299689 | Malignant Melan... | Denileukin dift... | 18 Years - | James Graham Brown Cancer Center | |
| Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) | NCT00211198 | Lymphoma, T-Cel... | ONTAK (denileuk... | 18 Years - | Eisai Inc. | |
| A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer | NCT00726037 | Metastatic Panc... | Ontak | 18 Years - | Loyola University | |
| Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak) | NCT01432483 | Cancer | Denileukin dift... | - | Eisai Inc. | |
| Vaccination Plus Ontak in Patients With Metastatic Melanoma | NCT00515528 | Melanoma | 4-peptide melan... Ontak | 18 Years - | University of Chicago | |
| Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak) | NCT01432483 | Cancer | Denileukin dift... | - | Eisai Inc. | |
| Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL) | NCT00051025 | Non-Hodgkin's L... Lymphoma, B-cel... Lymphoma, Low-g... | ONTAK | 18 Years - | Eisai Inc. | |
| Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cells | NCT00224354 | CHRONIC LYMPHOC... | IL-2 secreting ... IL-2 CD40L ONTAK immunotoxin dos... | 18 Years - | Baylor College of Medicine | |
| Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) | NCT00493129 | Leukemia Systemic Mastoc... | Ontak (Denileuk... | - | M.D. Anderson Cancer Center | |
| Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia | NCT00117845 | Leukemia, Adult... | Denileukin dift... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment | NCT00425672 | Male Breast Can... Recurrent Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | ONTAK flow cytometry immunohistochem... enzyme-linked i... laboratory biom... protein express... | 18 Years - | University of Washington | |
| Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL) | NCT00051025 | Non-Hodgkin's L... Lymphoma, B-cel... Lymphoma, Low-g... | ONTAK | 18 Years - | Eisai Inc. | |
| Denileukine Diftitox for Relapsed ALCL | NCT00801918 | Anaplastic Larg... | Denileukin Dift... Denileukin dift... | 2 Years - 24 Years | Columbia University | |
| Phase II Trial of Ontak With Metastatic Melanoma | NCT00299689 | Malignant Melan... | Denileukin dift... | 18 Years - | James Graham Brown Cancer Center | |
| Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) | NCT00493129 | Leukemia Systemic Mastoc... | Ontak (Denileuk... | - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
